School of Pharmacy and Biomedical Sciences

Staff

Dr Asmita Sautreau

  • Qualifications: BSc in Pharmacy, PhD, MRPharmS, SRPharmS, AFHEA
  • Role Title: Principal Lecturer
  • Address: University of Portsmouth, St Michael's Building, White Swan Road, Portsmouth, PO1 2DT
  • Telephone: 023 9284 3528
  • Email: asmita.sautreau@port.ac.uk
  • Department: School of Pharmacy and Biomedical Sciences
  • Faculty: Faculty of Science

Biography

I am a pharmacist from my first degree (1981) and thereafter obtained membership of the Royal Pharmaceutical Society (1982). I have worked as a pharmacist over the years, but got interested in natural products as result of the PhD programme that I undertook ('Microbial Transformation of Spirostanes and Related Compounds’, 1987). My senior lecturer appointment as a member of staff in this institution was in 1988. After a number of years, in 2001 there was opportunity to obtain Membership of the Institute of Learning and Teaching (now known as Higher Education Academy), as it was called then (Currently known by Higher Education Academy). I became Principal Lecturer in 2004 after taking on the responsibility as Course Leader of the Master of Pharmacy programme. Presently, I continue professionally as an academic pharmacist, still maintain a research profile and continue my administration input for the Master of Pharmacy programme.

Teaching Responsibilities

Natural products provide an immense range of compounds, from very simple molecules, for instance monoterpenes, fatty acids and phenolic compounds such as salicylic acid, to more complex structures such alkaloids, glycosides, lignans and flavonoids. My main focus for the teaching area is natural products, as a key source of medicinal compounds.  In addition, how these compounds can be templates to provide a range of semi-synthetic derivatives that are routinely used as therapeutic agents in medicine. There is an obvious link of natural products and phytotherapy. This is illustrated with concepts of phytotherapy and examples of herbs that cross the boundary. Furthermore, I am interested in plants that are known to have a toxic profile. I also take an interest in topics relating to medicinal chemistry and illustrate mechanism-based enzyme inhibition as the finesse for controlling specific disease conditions.

I take an interest in new students that join the MPharm programme and hence are involved with a number of other interests and activities. For instance, I oversee the skills-based unit as unit co-ordinator and I am involved with Pharmaceutical Chemistry laboratory classes for level 4. I liaise and communicate with many employers to invite them to career based events for all students, such as the pharmacy careers event, information sessions for employers to provide guidance to students and many other events.

Research Interests

My main area of interest in the pharmaceutical context is natural products, especially those from plants which provide a huge diversity of unique structures, many of which have a niche in therapeutic and clinical treatment of various types of medical conditions.

Hence, my research area focuses on natural products with particular interest in isolating and identifying bioactive compounds from plants. These are plant secondary metabolites and identification entails bioassay-guided fractionation linked to spectroscopic and other techniques. The research projects are varied, such as study of selected plant species of the family Euphorbiaceae to control the spread of parasitic disease in particular schistosomiasis, study of specific chemotaxonomic markers, utilizing specifically biologically inherited compounds within a species to standardise herbal preparations, and investigating herbal remedies e.g. raspberry leaves as potential for treatment of irritable bowel syndrome and species related to St. John’s Wort for antimicrobial application.

Publications

View all publications on Parade…

Presentations

  • W. A. Alsulmy, C. W. Wright, G. Blunden and A. Patel, “Antiplasmodial and molluscicidal activity of two species of marine macro-algae”, Royal Society of Chemistry Postgraduate Symposium, University of Bradford, October 2012.
  • G. Id Daoud, M. Devonshire, P. Gurung, B.Veron, A. V. Patel, J. Pope, P. K. Hayes and C. Hellio, “Development of bioassays for assessing antifouling activity of biogenic compounds extracted from marine microalgae”, 60th Annual Winter Meeting of the British Phycological Society, University of Newcastle, January 2012.
  • D. Wright, A.V. Patel, J Rice and P.J. Newland-Jones, “Evaluation of cytotoxic activity in a human cell line of extracts from two Euphorbia species which display molluscicidal activity”, British Occupational Hygiene Society Conference, Stratford Upon Avon, April 2011.
  • G. Id Daoud, B. Véron, E. Beach, J. Kudyk, B. Banaigs, A. V. Patel, J. Pope, P.K. Hayes and  C. Hellio, “Biological activity and chemical fingerprinting of microalgae extracts for antifouling application”, 5th European Phycological Congress, Rhodes Island, Greece, September 2011.

Collaborations

Over the years I have collaborated with a number of research groups in countries such as Russia, Indonesia, Venezuela, the United Arab Emirates (UAE), Hungary and the Czech Republic. There is co-operation also within the School/University to bring different expertise together in order to maximise the potential of the projects.

Postgraduate Research Supervised

Ms Jai Ma, “Chemical Profile evaluation of selected species of Panax, Epimedium, Rhodiola and Eleuthero, to devise quality control criteria for their formulated products”.

Ms Rebecca O'Cleirigh, “Exploring possible mechanisms of action of the TCM formula Gui Shao Di Huang Wan in relation to the haematological aspects of endometrial receptivity”.

Mr Chengyin Yu, “Explore the mechanism of Berberine8998 (Derivative of Berberine) Lipid-lowering Activities”.

Memberships

  • General Pharmaceutical Council
  • Royal Pharmaceutical Society
  • Academic Pharmacy Group RPS and Associate Fellow of the Higher Education Academy
  • Member of Pharmaceutical Scientist
  • Member of The joint Pharmaceutical Analysis Group